Format

Send to

Choose Destination
J Surg Oncol. 2019 Aug 26. doi: 10.1002/jso.25681. [Epub ahead of print]

Survival benefit of neoadjuvant therapy in patients with non-metastatic pancreatic ductal adenocarcinoma: A propensity matching and intention-to-treat analysis.

Author information

1
Division of Hepatobiliary and Pancreas Surgery, Mayo Clinic, Rochester, Minnesota.
2
Department of Hepatobiliary and Pancreatic Surgery, National Cancer Center Hospital East, Kashiwa, Japan.
3
Division of Radiology, Mayo Clinic, Rochester, Minnesota.
4
Division of Pathology, Mayo Clinic, Rochester, Minnesota.
5
Division of Gastroenterology and Hepatology, Mayo Clinic, Rochester, Minnesota.
6
Division of Biomedical Statistics and Informatics, Mayo Clinic, Rochester, Minnesota.

Abstract

BACKGROUND AND OBJECTIVES:

Conclusive evidence in favor of neoadjuvant therapy for those with non-metastatic pancreatic ductal adenocarcinoma (PDAC) is still lacking. The objective of this study was to evaluate the survival benefit of neoadjuvant therapy vs upfront surgery for patients with non-metastatic PDAC.

METHODS:

The study involved 565 patients undergoing neoadjuvant therapy or upfront surgery as the primary treatment for PDAC. Propensity score matching was performed between the neoadjuvant therapy group (NAT group) and the upfront surgery group (UFS group) using 20 clinical variables at diagnosis. Overall survival and surgical pathology were compared between the two treatment groups on an intent-to-treat basis.

RESULTS:

In the matched cohort, the NAT group (n = 91) had a longer median overall survival than the UFS group (n = 91) (23.1 months vs 18.5 months, P = .043). The rate of patients undergoing surgical resection was lower in the NAT group (58% vs 80%, P = .001). Regarding surgical pathology, the NAT group had smaller tumor size (2.8 cm vs 4.0 cm, P = .001), lower incidence of positive surgical margins (8% vs 30%, P < .002), and less lymph node metastasis (45% vs 78%, P < .001).

CONCLUSIONS:

The strategy of neoadjuvant therapy before surgical resection appears to offer pathologic effect and survival benefit for the patients presenting with non-metastatic PDAC.

KEYWORDS:

neoadjuvant therapy; overall survival; pancreatic cancer; surgical resection; upfront surgery

PMID:
31452208
DOI:
10.1002/jso.25681

Supplemental Content

Loading ...
Support Center